))
Experimental Talazoparib Seems Better Than Chemotherapy for Metastatic HER2-Negative Disease in Women With a BRCA Mutation
Manage episode 365353078 series 3482052
Breastcancer.org에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Breastcancer.org 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Jennifer Litton, associate professor of breast Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the results of the EMBRACA study she presented at the 2017 San Antonio Breast Cancer Symposium showing that talazoparib, an experimental targeted therapy medicine, improved the time until the cancer grew in women with a BRCA1 or BRCA2 mutation who had been diagnosed with metastatic HER2-negative breast cancer compared to chemotherapy.
Listen to the podcast to hear Dr. Litton explain:
- how talazoparib works
- whether talazoparib will offer benefits to women with other mutations linked to a higher risk of breast cancer
- how the side effects differed between talazoparib and chemotherapy
- why quality of life was better in women who were treated with talazoparib
Editor's Note: Talzenna (chemical name: talazoparib) was approved by the U.S. Food and Drug Administration on Oct. 16, 2018, for the treatment of metastatic breast cancer in women with BRCA mutations. Learn more about Talzenna.
349 에피소드
공유
